TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9725547

Group type: EXPERIMENTAL
Intervention: 0.1 mg cerivastatin daily for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study: 7994829

Group type: EXPERIMENTAL
Intervention: Encainide or Flecainide (active therapy)
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Moricizine (active therapy)
Number of subjects: 1991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1991
Study: 2845305

Group type: EXPERIMENTAL
Intervention: Single-shot CMV hyperimmunoglobulin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha 2
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30906977

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study: 27377678

Group type: EXPERIMENTAL
Intervention: Fish (TMAO source)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eggs (choline source)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Beef (carnitine source)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fruit (control)
Number of subjects: 40
Study: 25772766

Group type: EXPERIMENTAL
Intervention: NAVIGATE program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 0
Study: 23604013

Group type: EXPERIMENTAL
Intervention: Presentation of radiation exposure/health risk information
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Presentation of Medicare reimbursement information
Number of subjects: 112

Group type: COMPARATOR
Intervention: Initial imaging choice without guideline recommendations
Number of subjects: 112
Study: 21307142

Group type: COMPARATOR
Intervention: recFSH started on cycle day 2 (CD2)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: recFSH started on cycle day 5 (CD5)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (CD2 and CD5)
Number of subjects: 76
Study: 19812460

Group type: EXPERIMENTAL
Intervention: Intensive, computer‐based cognitive training (100 min/d, 5 d/wk for 6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Passive computer activities (reading, listening, visuospatial game) for similar amounts of time
Number of subjects: 47
Study: 16903198

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) (Group 2)
Number of subjects: 90
Study: 14703540

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with adequate allocation concealment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with intention to treat analysis
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with sample size calculation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials with clearly defined endpoints and prespecified alpha and beta errors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Reporting of drop outs in randomised controlled trials
Number of subjects: 56
Study: 11679144

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 9855480

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK-8) infusion (4 ng/kg/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study: 7925258

Group type: EXPERIMENTAL
Intervention: Maximal effort, 80%, 60%, 40%, and 20% (of the maximal) effort in pinching, gripping and stoop lifting for three trials.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perceived 60% and 80% of maximal voluntary contractions (MVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perceived 20% of maximal voluntary contractions (MVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perceived 40% effort
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reliability of perception
Number of subjects: 10
Study: 2680581

Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline powder by Bricanyl Turbuhaler
Number of subjects: 22

Group type: COMPARATOR
Intervention: 5 mg terbutaline by a conventional jet nebulizer (Pari Inhalierboy)
Number of subjects: 22
Study: 1092245

Group type: EXPERIMENTAL
Intervention: Ru‐Vert (25 mg pentylenetetrazol, 12.5 mg pheniramine maleate, 50 mg nictonic acid) at a dosage of two tablets t.i.d.
Number of subjects: 17
Study: 31866471

Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study: 31669450

Group type: EXPERIMENTAL
Intervention: Patient navigation (PN)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 754
Study: 29069041

Group type: COMPARATOR
Intervention: fiber-free nutrition formula (FF group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: fiber-enriched nutrition formula (FE group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: fiber- and probiotic-enriched nutrition formula (FEP group)
Number of subjects: 120
Study: 25355774

Group type: EXPERIMENTAL
Intervention: Combined antibacterial and fluoride therapy
Number of subjects: 109
Study: 23916716

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (RT) with cisplatin 20mg/m(2) chemotherapy on 5 consecutive days during weeks 1 and 5 or 6 of RT
Number of subjects: 136

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (RT) without cisplatin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (RT) with or without cisplatin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Good response (CR/Cru)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Good response at primary tumor and lymph nodes
Number of subjects: 136
Study: 21823568

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 0
Study: 19349314

Group type: EXPERIMENTAL
Intervention: Delta9‐Tetrahydrocannabinol (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16920653

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 429
Study: 15232792

Group type: EXPERIMENTAL
Intervention: Intensive dietary counseling
Number of subjects: 41

Group type: COMPARATOR
Intervention: Special oral liquid nutritional supplement (Nepro)
Number of subjects: 41
Study: 15540421

Group type: COMPARATOR
Intervention: Methotrexate (MT) 7.5-10.0 mg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prednisolone (P) ≥ 10 mg/day + Methotrexate (MT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Methotrexate (MT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prednisolone (P) + Methotrexate (MT)
Number of subjects: 62
Study: 11137255

Group type: EXPERIMENTAL
Intervention: ISCOM vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional non‐adjuvanted inactivated split virion vaccine
Number of subjects: 0
Study: 9143211

Group type: EXPERIMENTAL
Intervention: DHS questions
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: NSFG questions
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Discordant responses to DHS and NSFG questions
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Predictive factors
Number of subjects: 2352
Study: 1606331

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine 2400 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/d and Cimetidine 2400 mg/d (combined therapy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Drug-free
Number of subjects: 8
Study: 3456797

Group type: EXPERIMENTAL
Intervention: Upper removable appliance
Number of subjects: 22

Group type: COMPARATOR
Intervention: Upper fixed appliance
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lower fixed appliance
Number of subjects: 22
Study: 3041944

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.25%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.125%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All concentrations of apraclonidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apraclonidine (all concentrations)
Number of subjects: 20
Study: 31468059

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 29469713

Group type: EXPERIMENTAL
Intervention: Video-based education
Number of subjects: 39

Group type: COMPARATOR
Intervention: Verbal education
Number of subjects: 39
Study: 25601762

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (multiple doses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pooled data from three additional independent GWAS studies
Number of subjects: 120
Study: 23284074

Group type: EXPERIMENTAL
Intervention: lactate-based low-GDP solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: lactate-based high-GDP solution
Number of subjects: 60
Study: 21312255

Group type: EXPERIMENTAL
Intervention: Spectra Optia
Number of subjects: 32

Group type: COMPARATOR
Intervention: MCS+
Number of subjects: 32
Study: 19602185

Group type: EXPERIMENTAL
Intervention: Eccentric exercises for the calf muscles
Number of subjects: 3
Study: 18057662

Group type: EXPERIMENTAL
Intervention: Calcimimetics
Number of subjects: 0
Study: 15780527

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with estradiol 17‐valerate 2 mg for the first 11 days and estradiol 17‐valerate 2 mg plus ciproterone acetate 1 mg for the next 10 days, administered for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 40
Study: 11517122

Group type: EXPERIMENTAL
Intervention: Continuous morphine (CM, 10 microg x kg(‐1) x h(‐1)) with three‐hourly placebo boluses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent morphine (IM, 30 microg x kg(‐1) every 3 h) with a placebo infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative plasma concentrations of norepinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative plasma concentrations of lactate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative plasma concentrations of epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative plasma concentrations of insulin
Number of subjects: 0
Study: 10197215

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swallowed beclomethasone dipropionate (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metered dose inhaler with large volume spacer (2 mg beclomethasone dipropionate)
Number of subjects: 0
Study: 7852620

Group type: EXPERIMENTAL
Intervention: Electronic Dental Analgesia (EDA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3391341

Group type: EXPERIMENTAL
Intervention: Sleeping medication alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sleeping medication with 5.0 mg methscopolamine bromide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control night (no methscopolamine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methscopolamine administration
Number of subjects: 8
Study: 31571853

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.2 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28781026

Group type: EXPERIMENTAL
Intervention: Low-Dose Statin + Armolipid Plus (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-Dose Statin (n=50)
Number of subjects: 100
Study: 25658973

Group type: EXPERIMENTAL
Intervention: Instructed extinction and removal of the shock electrode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Detailed description of the experimental scenario
Number of subjects: 0
Study: 23446901

Group type: EXPERIMENTAL
Intervention: Caribbean starch dietary pattern
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fruit and vegetables dietary pattern
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Pizza and sweets dietary pattern
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Meat dietary pattern
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fried food dietary pattern
Number of subjects: 235
Study: 21216310

Group type: EXPERIMENTAL
Intervention: HIVIS DNA vaccine (arm B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HAART (arm A)
Number of subjects: 20
Study: 19638214

Group type: EXPERIMENTAL
Intervention: Mindfulness training (8-week program based on Mindfulness-based Stress Reduction [MBSR])
Number of subjects: 87

Group type: COMPARATOR
Intervention: Social-support group (attention-control condition)
Number of subjects: 87
Study: 16626544

Group type: EXPERIMENTAL
Intervention: rhBNP (1.5 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(‐1).mn(‐1) for the first 3 hours and 0.015‐0.03 microg.kg(‐1).mn(‐1) infusion for following 21 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: NIT (10 to 100 microg/mn intravenous infusion for 24 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Total urine output
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACE)
Number of subjects: 42
Study: 15380463

Group type: EXPERIMENTAL
Intervention: Forearm blood flow (FBF) during reactive hyperemia
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Serum angiotensin-converting enzyme (ACE) activity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Serum concentrations of nitrite/nitrate
Number of subjects: 110
Study: 11687453

Group type: EXPERIMENTAL
Intervention: Immune milk (n = 4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonimmune milk (Control group, n = 4)
Number of subjects: 8
Study: 9644823

Group type: EXPERIMENTAL
Intervention: Implicit skill acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit skill acquisition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induced anxiety
Number of subjects: 0
Study: 7943116

Group type: EXPERIMENTAL
Intervention: Butorphanol (1 to 2 mg hourly on request)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl (50 to 100 micrograms hourly on request)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both drugs (Butorphanol and Fentanyl)
Number of subjects: 100
Study: 3605567

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam 0.25 mg/kg
Number of subjects: 50
Study: 31397770

Group type: EXPERIMENTAL
Intervention: Outpatient Cardiac Rehabilitation (OCR), 20 sessions
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 28544222

Group type: EXPERIMENTAL
Intervention: PCR-based sequencing to detect clarithromycin resistance-associated mutations using fecal samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA of isolated strains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy including clarithromycin
Number of subjects: 0
Study: 24973894

Group type: EXPERIMENTAL
Intervention: Baclofen at 80 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23608190

Group type: EXPERIMENTAL
Intervention: Screening Checklist for Auditory Processing (SCAP)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Screening Test for Auditory Processing (STAP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Comparison of SCAP and STAP
Number of subjects: 400

Group type: COMPARATOR
Intervention: SCAP and auditory memory subsection of STAP
Number of subjects: 400
Study: 21318566

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg oral)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Methamphetamine (0.42 mg/kg oral)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19403636

Group type: EXPERIMENTAL
Intervention: Dietary Modification intervention (n = 19,541; daily goal: < or =20% of energy as fat, > or =5 servings of vegetables and fruit, and > or =6 servings of grains)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Dietary Modification intervention (n = 19,541)
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group (n = 29,294; no dietary changes)
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group (n = 29,294)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Subset of women (n = 3951)
Number of subjects: 48835
Study: 17435550

Group type: EXPERIMENTAL
Intervention: High- or moderate-volume center with D1 or D2 dissection
Number of subjects: 448

Group type: COMPARATOR
Intervention: Low-volume hospital with D1 or D2 dissection
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: D0 resection
Number of subjects: 448
Study: 15118464

Group type: EXPERIMENTAL
Intervention: dorzolamide + timolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dorzolamide + acetazolamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: acetazolamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dorzolamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: vehicle alone
Number of subjects: 30
Study: 11298623

Group type: COMPARATOR
Intervention: trk C immunoreactive neurones in control infant colon
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: trk C immunoreactive neurones in normoganglionic Hirschsprung's disease
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: trk C immunoreactive neurones in STC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sural nerve abnormalities in STC
Number of subjects: 16
Study: 10592815

Group type: EXPERIMENTAL
Intervention: TETRAMUNE (HibTITER with whole‐cell DTP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DTP and HibTITER administered concurrently
Number of subjects: 90
Study: 8200716

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 10
Study: 3067834

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study: 30031454

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (7 group sessions including a cooking class)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study: 27193768

Group type: EXPERIMENTAL
Intervention: Capacity Enhancement (CE) intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard Dissemination (SD) condition
Number of subjects: 31
Study: 23871120

Group type: EXPERIMENTAL
Intervention: Errorless learning (ELL) and spaced retrieval (SR) cognitive techniques, trained twice a week for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 20
Study: 22336574

Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for hydrocortisone
Number of subjects: 10
Study: 20375291

Group type: EXPERIMENTAL
Intervention: 16 hours of supplemental reading intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 18297478

Group type: EXPERIMENTAL
Intervention: Staff education
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Staff education and peer support
Number of subjects: 52
Study: 15797165

Group type: EXPERIMENTAL
Intervention: Regression-based prediction formulas for RBANS subtests
Number of subjects: 223
Study: 11914101

Group type: EXPERIMENTAL
Intervention: l-NMMA (3 mg.h(‐1).kg(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenylephrine (12‐36 microg.h(‐1).kg(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitrate+nitrite levels in plasma
Number of subjects: 24
Study: 10695206

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway insertion by trained nurses
Number of subjects: 212

Group type: COMPARATOR
Intervention: Nasopharyngeal airway insertion by anesthesiologists
Number of subjects: 212
Study: 8561215

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 1414897

Group type: EXPERIMENTAL
Intervention: Liposorber LA-15 System (LDL apheresis)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (standard diet and drug therapy)
Number of subjects: 64
Study: 4064517

Group type: EXPERIMENTAL
Intervention: Dehydration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal hydration
Number of subjects: 100
Study: 31176289

Group type: EXPERIMENTAL
Intervention: Impella CP transvalvular microaxial flow pump
Number of subjects: 100

Group type: COMPARATOR
Intervention: Current guideline-driven therapy
Number of subjects: 100
Study: 29258695

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 480
Study: 24485882

Group type: EXPERIMENTAL
Intervention: Children with spastic cerebral palsy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 25
Study: 23469629

Group type: COMPARATOR
Intervention: Standard treatment for HCV (Pegylated interferon and Ribavirin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standard treatment plus Fluvastatin (80 mg/daily)
Number of subjects: 80
Study: 20167584

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% for Group A (BMI >27 kg/m²)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% for Group B (BMI 24-27 kg/m²)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% for Group C (BMI <24 kg/m²)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of Group A vs Group C
Number of subjects: 21
Study: 17414745

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 34